Moracin O是一种从Morus alba Linn.中分离出来的,具有显著抗炎和抗氧化活性的缺氧诱导因子(HIF-1)抑制剂。
Cas No.:123702-97-6
Sample solution is provided at 25 µL, 10mM.
Moracin O is a hypoxia-inducible factor (HIF-1) inhibitor isolated from Morus alba Linn., exhibiting significant anti-inflammatory and antioxidant activities[1,2]. Moracin O reduces reactive oxygen species (ROS) generation induced by oxygen-glucose deprivation (OGD)[3] and is commonly used in studies of neuroprotection, oxidative stress, and the regulation of related signaling pathways[4,5].
In vitro, treatment of 4T1-NF-κB reporter cells with Moracin O (3, 10, 100nM) for 24h dose-dependently inhibited NF-κB activity. Pretreatment of HaCaT human keratinocytes with Moracin O (10μM) for 1h, followed by co-incubation with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, 20ng/mL) for 24h, significantly attenuated TRAIL-induced cell damage and improved cell viability[6]. Pretreatment of SK-N-SH human neuroblastoma cells with Moracin O (10μM) for 4h, followed by exposure to 30mM glutamate for 4h, significantly inhibited glutamate-induced cell death[7].
In vivo, Institute of Cancer Research (ICR) mice were pretreated with Moracin O (80mg/kg, i.p.) 30min prior to the injection of 0.7% acetic acid to induce a pain model. Moracin O significantly inhibited acetic acid-induced writhing responses, reducing the mean number of writhes from 17 ± 6 in the control group to 0 ± 1, with an inhibition rate of 98%[7].
References:
[1] NAIK R, HARMALKAR D S, XU X, et al. Bioactive benzofuran derivatives: Moracins A-Z in medicinal chemistry[J]. European Journal of Medicinal Chemistry, 2015, 90: 379-393.
[2] DAT N T, JIN X, LEE K, et al. Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived Diels–Alder adducts from Morus species[J]. Journal of Natural Products, 2009, 72(1): 39-43.
[3] LEE H J, LYU D H, KOO U, et al. Inhibitory effect of 2-arylbenzofurans from the Mori Cortex Radicis (Moraceae) on oxygen glucose deprivation (OGD)-induced cell death of SH-SY5Y cells[J]. Archives of Pharmacal Research, 2011, 34(8): 1373-1380.
[4] LEE J H, KO H J, WOO E R, et al. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo[J]. European Journal of Pharmacology, 2016, 783: 64-72.
[5] ZOOFISHAN Z, KÚSZ N, CSORBA A, et al. Antispasmodic activity of prenylated phenolic compounds from the root bark of Morus nigra[J]. Molecules, 2019, 24(13): 2497.
[6] HARDIANTI B, UMEYAMA L, LI F, et al. Anti-inflammatory compounds moracin O and P from Morus alba Linn. (Sohakuhi) target the NF-κB pathway[J]. Molecular Medicine Reports, 2020, 22(6): 5385-5391.
[7] WANG Y N, LIU M F, HOU W Z, et al. Bioactive benzofuran derivatives from Cortex Mori Radicis, and their neuroprotective and analgesic activities mediated by mGluR1[J]. Molecules, 2017, 22(2): 236.
Moracin O是一种从Morus alba Linn.中分离出来的,具有显著抗炎和抗氧化活性的缺氧诱导因子(HIF-1)抑制剂[1,2]。Moracin O可减少氧糖剥夺(OGD)诱导的活性氧(ROS)生成[3],通常用于神经保护、氧化应激及相关信号传导通路调控的研究[4,5]。
在体外,Moracin O(3, 10, 100nM)处理4T1NF-κB报告细胞株24h,剂量依赖性地抑制了NF-κB的活性。Moracin O(10μM)预处理HaCaT人角质形成细胞1h,随后加入肿瘤坏死因子相关凋亡诱导配体(TRAIL, 20ng/mL)共培养24h,显著减轻了TRAIL诱导的细胞损伤,提高了细胞存活率[6]。Moracin O(10μM)预处理SK-N-SH 人神经母细胞瘤4h,随后加入30mM谷氨酸处理4h,显著抑制了谷氨酸诱导的细胞死亡[7]。
在体内,Moracin O(80mg/kg)通过腹腔注射预先30min处理Institute of Cancer Research(ICR)小鼠,随后注射0.7%乙酸诱导疼痛模型,显著抑制了乙酸诱导的扭体反应,平均扭体次数从对照组的17 ± 6次降至0 ± 1次,抑制率达98%[7]。
| Cell experiment [1]: | |
Cell lines | HaCaT cells |
Preparation Method | HaCaT cells were pre-incubated with 10µM of Moracin O for 1h, then co-cultured with 20ng/mL TRAIL for 24h. Cell viability was determined using a WST-1 assay and normalized to the untreated control. |
Reaction Conditions | 10μM; 1h |
Applications | Pretreatment with Moracin O significantly reduced TRAIL-induced cell damage and improved cell survival. |
| Animal experiment [2]: | |
Animal models | Male ICR mice |
Preparation Method | ICR mice were pretreated intraperitoneally (i.p.) with the Moracin O (80mg/kg) in a separate set 30 min before acetic acid injection (0.7%). The mice were placed individually into glass beakers and 5min were allowed to elapse. The mice were then observed for a period of 10min and the number of writhes was recorded for each animal. |
Dosage form | 80mg/kg; i.p. |
Applications | Pretreatment with Moracin O significantly inhibited acetic acid-induced writhing responses, reducing the average number of writhing responses from 17 ± 6 in the control group to 0 ± 1, with an inhibition rate of 98%. |
References: | |
| Cas No. | 123702-97-6 | SDF | |
| 别名 | 桑辛素O | ||
| 分子式 | C19H18O5 | 分子量 | 326.34 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0643 mL | 15.3214 mL | 30.6429 mL |
| 5 mM | 612.9 μL | 3.0643 mL | 6.1286 mL |
| 10 mM | 306.4 μL | 1.5321 mL | 3.0643 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















